• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

It's far better to be alone than to be in bad company.

作者信息

Duruisseaux Michael, Cadranel Jacques

机构信息

Respiratory Department, Louis Pradel Hospital, Hospices Civils de Lyon Cancer Institute, Lyon, France.

Anticancer Antibodies Lab, Cancer Research Center of Lyon, Lyon, France.

出版信息

J Thorac Dis. 2019 Mar;11(3):649-651. doi: 10.21037/jtd.2019.02.65.

DOI:10.21037/jtd.2019.02.65
PMID:31019750
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6462733/
Abstract
摘要

相似文献

1
It's far better to be alone than to be in bad company.独处远比与坏人为伍好得多。
J Thorac Dis. 2019 Mar;11(3):649-651. doi: 10.21037/jtd.2019.02.65.
2
Commentary: It's better to be alone than in bad company…at least for bioprosthesis.评论：独处总比与不良同伴在一起要好……至少对于生物假体来说是这样。
J Thorac Cardiovasc Surg. 2023 Feb;165(2):618-619. doi: 10.1016/j.jtcvs.2021.02.048. Epub 2021 Feb 19.
3
Sunlight; it's good and it's bad.阳光；它有好处也有坏处。
Am J Nurs. 1954 Jun;54(6):696-7.
4
It's aneurysmal, it's stenotic, it's tuberculosis.
Med J Malaysia. 2011 Dec;66(5):515-6.
5
The last taboo. It's not sex. It's not drinking. It's stress--and it's soaring.最后的禁忌。不是性。不是饮酒。是压力——而且压力正在飙升。
Fortune. 2002 Oct 28;146(8):136-8, 140, 142 passim.
6
By the way, doctor... A local hospital is advertising that I can get a CT scan of my entire body for $700. If it's negative, they say that shows that I don't have cancer. My insurance company won't cover this, but it seems like it might be worth the money if one of these scans can find something. Do you think it's a good idea?顺便问一下，医生……一家当地医院在做广告，说我花700美元就能做一次全身CT扫描。如果结果是阴性，他们说那就表明我没有癌症。我的保险公司不承保这个，但如果这样一次扫描能发现什么问题的话，似乎这笔钱花得还是值得的。你觉得这是个好主意吗？
Harv Health Lett. 2000 Nov;26(1):8.
7
It's me grandma! it's me! Eileen Mitchell It's me grandma! it's me! Alzheimer's Society £4.95 20pp 9781906647117 Product code 1004 [Formula: see text].是我，奶奶！是我！艾琳·米切尔 是我，奶奶！是我！阿尔茨海默病协会 4.95英镑 20页 9781906647117 产品代码1004 [配方：见正文]
Nurs Older People. 2011 Sep 1;23(7):8. doi: 10.7748/nop.23.7.8.s3.
8
It's Bad-Really Bad-But Does it Matter? Medication Adherence in Chronic Obstructive Pulmonary Disease.情况很糟——真的很糟——但这重要吗？慢性阻塞性肺疾病的药物依从性
Am J Respir Crit Care Med. 2017 May 15;195(10):1282-1283. doi: 10.1164/rccm.201608-1592ED.
9
The new ABCs of AV block. A revised classification to remove the mental block from recognizing AV block.房室传导阻滞的新ABCs。一种修订的分类方法，以消除识别房室传导阻滞时的思维障碍。
JEMS. 2002 Feb;27(2):24-34.
10
It's Horrible - It's Beautiful - It's Rowing.它很可怕——它很美妙——它是赛艇运动。
Phys Sportsmed. 1975 May;3(5):103-107. doi: 10.1080/00913847.1975.11948199.

本文引用的文献

1
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.转移性非小细胞肺癌：欧洲肿瘤内科学会临床实践诊断、治疗及随访指南
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237. doi: 10.1093/annonc/mdy275.
2
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.TP53 突变状态对 ALK 重排非小细胞肺癌系统治疗结局的影响。
Ann Oncol. 2018 Oct 1;29(10):2068-2075. doi: 10.1093/annonc/mdy333.
3
Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma.- 突变与 PD-1 抑制剂耐药在 - 突变型肺腺癌中的研究进展
Cancer Discov. 2018 Jul;8(7):822-835. doi: 10.1158/2159-8290.CD-18-0099. Epub 2018 May 17.
4
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.一线克唑替尼对比化疗用于 ALK 基因突变阳性非小细胞肺癌的研究的最终总生存分析。
J Clin Oncol. 2018 Aug 1;36(22):2251-2258. doi: 10.1200/JCO.2017.77.4794. Epub 2018 May 16.
5
Clinical and Pathological Characteristics of - and -Mutated Non-Small Cell Lung Carcinoma (NSCLC).伴有 - 和 - 基因突变的非小细胞肺癌（NSCLC）的临床和病理特征。
Clin Cancer Res. 2018 Jul 1;24(13):3087-3096. doi: 10.1158/1078-0432.CCR-17-3416. Epub 2018 Apr 3.
6
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.晚期表皮生长因子受体（EGFR）突变型肺癌中共发基因改变的演变及其临床影响
Nat Genet. 2017 Dec;49(12):1693-1704. doi: 10.1038/ng.3990. Epub 2017 Nov 6.
7
Effects of Co-occurring Genomic Alterations on Outcomes in Patients with -Mutant Non-Small Cell Lung Cancer.- 突变型非小细胞肺癌患者中共同发生的基因组改变对结局的影响。
Clin Cancer Res. 2018 Jan 15;24(2):334-340. doi: 10.1158/1078-0432.CCR-17-1841. Epub 2017 Oct 31.
8
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.克唑替尼与新一代ALK抑制剂用于ALK阳性非小细胞肺癌的总生存期（IFCT-1302 CLINALK）：一项法国全国队列回顾性研究
Oncotarget. 2017 Mar 28;8(13):21903-21917. doi: 10.18632/oncotarget.15746.
9
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).常规对晚期非小细胞肺癌患者进行分子谱分析：法国胸科协作组（IFCT）进行的为期 1 年的全国性计划的结果。
Lancet. 2016 Apr 2;387(10026):1415-1426. doi: 10.1016/S0140-6736(16)00004-0. Epub 2016 Jan 15.
10
Is there a specific phenotype associated with the different subtypes of KRAS mutations in patients with advanced non-small-cell lung cancers?在晚期非小细胞肺癌患者中，KRAS突变的不同亚型是否存在特定的表型？
Lung Cancer. 2015 Dec;90(3):561-7. doi: 10.1016/j.lungcan.2015.10.012. Epub 2015 Oct 14.